A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

NCT07075484 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Hemolytic Anemia

Interventions

DRUG: YTS109 cell

Sponsor

China Immunotech (Beijing) Biotechnology Co., Ltd.

Collaborators

[object Object]